168 related articles for article (PubMed ID: 31646247)
1. Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant.
Meewan I; Zhang X; Roy S; Ballatore C; O'Donoghue AJ; Schooley RT; Abagyan R
ACS Omega; 2019 Oct; 4(16):16999-17008. PubMed ID: 31646247
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
3. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
[TBL] [Abstract][Full Text] [Related]
4. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.
Asante-Appiah E; Curry S; McMonagle P; Ingravallo P; Chase R; Nickle D; Qiu P; Howe A; Lahser FC
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416549
[TBL] [Abstract][Full Text] [Related]
5. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
Lin C; Kwong AD; Perni RB
Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
[TBL] [Abstract][Full Text] [Related]
6. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
Xue W; Ban Y; Liu H; Yao X
J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
[TBL] [Abstract][Full Text] [Related]
7. High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple hepatitis C virus genotypes.
Lee H; Zhu T; Patel K; Zhang YY; Truong L; Hevener KE; Gatuz JL; Subramanya G; Jeong HY; Uprichard SL; Johnson ME
PLoS One; 2013; 8(10):e75144. PubMed ID: 24130685
[TBL] [Abstract][Full Text] [Related]
8. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.
Boonma T; Nutho B; Darai N; Rungrotmongkol T; Nunthaboot N
J Biomol Struct Dyn; 2022 Aug; 40(12):5283-5294. PubMed ID: 33430709
[TBL] [Abstract][Full Text] [Related]
9. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
Chen SH; Tan SL
Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
[TBL] [Abstract][Full Text] [Related]
10. GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.
Zhai PB; Qing J; Li B; Zhang LQ; Ma L; Chen L
Acta Pharmacol Sin; 2018 Nov; 39(11):1746-1752. PubMed ID: 29930277
[TBL] [Abstract][Full Text] [Related]
11. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
[TBL] [Abstract][Full Text] [Related]
12. Development and application of a fast, reproducible assay to measure HCV NS3 protease activity using Escherichia coli lysate.
Han B; Dvory-Sobol H; Greenstein A; McCarville JF; Hung M; Liu X; Miller MD; Mo H
J Virol Methods; 2015 Dec; 225():76-86. PubMed ID: 26391876
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel.
Chatel-Chaix L; Baril M; Lamarre D
Viruses; 2010 Aug; 2(8):1752-1765. PubMed ID: 21994705
[TBL] [Abstract][Full Text] [Related]
14. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
[TBL] [Abstract][Full Text] [Related]
15. Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V).
Ezat AA; El-Bialy NS; Mostafa HI; Ibrahim MA
Protein J; 2014 Feb; 33(1):32-47. PubMed ID: 24374429
[TBL] [Abstract][Full Text] [Related]
16. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
[TBL] [Abstract][Full Text] [Related]
17. Development of an efficient
Naguib MM; Mohamed MR; M Ali MA; Karim AM
Indian J Pathol Microbiol; 2019; 62(3):391-398. PubMed ID: 31361226
[TBL] [Abstract][Full Text] [Related]
18. Probing of exosites leads to novel inhibitor scaffolds of HCV NS3/4A proteinase.
Shiryaev SA; Cheltsov AV; Strongin AY
PLoS One; 2012; 7(7):e40029. PubMed ID: 22768327
[TBL] [Abstract][Full Text] [Related]
19. Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells.
Lee JC; Shih YF; Hsu SP; Chang TY; Chen LH; Hsu JT
Anal Biochem; 2003 May; 316(2):162-70. PubMed ID: 12711336
[TBL] [Abstract][Full Text] [Related]
20. Discovery of small molecule inhibitors against the NS3/4A serine protease of Hepatitis C virus genotype 3 via highthroughput virtual screening and in vitro evaluations.
Sakhor W; Teoh TC; Yusof R; Lim SK; Razif MFM
Trop Biomed; 2020 Sep; 37(3):609-625. PubMed ID: 33612776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
